REGISTER
HEC Pharm’s Class 1 Diabetes Drug Approved
HEC Pharm’s SGLT-2 inhibitor ologliflozin has been approved in China for glycemic control in adults with type 2 diabetes, marking the company’s first innovative glucose-lowering drug. The product showed durable HbA1c reductions and favorable tolerability in two Phase III trials after a decade-long development path.

On January 16, the NMPA website showed that HEC Pharm’s Class 1 new drug ologliflozin, formerly known as pyroglutamic acid rongliflozin, was approved in China to improve glycemic control in adults with type 2 diabetes. It is an SGLT-2 inhibitor and the first innovative glucose-lowering drug approved for marketing from HEC Pharm.

SGLT-2 refers to sodium-glucose cotransporter 2 in the renal tubules. By reducing renal glucose reabsorption and increasing urinary glucose excretion, SGLT-2 inhibitors lower blood glucose in a non-insulin-dependent manner, with a relatively low incidence of hypoglycemia. Beyond diabetes, they can also provide cardiovascular and renal protection. From 2018 to 2023, China’s SGLT-2 inhibitor market grew from RMB 500 million to RMB 10.5 billion, representing a compound annual growth rate of 83.5% and highlighting strong market potential.

According to the Insight database, HEC Pharm submitted its clinical trial application for ologliflozin as early as May 2015, with the first clinical study publicly disclosed in 2017, and did not file for marketing until 2024. Its approval today marks the culmination of a decade-long development journey and the official start of commercialization.

Ologliflozin demonstrated comprehensive and durable glucose-lowering efficacy in two Phase III trials. After 24 weeks of treatment, compared with placebo, HbA1c was reduced by 1.01% and 0.94% in the 50 mg and 20 mg monotherapy groups, respectively. Compared with data from other SGLT-2 inhibitors that had statistically meaningful 2-hour postprandial glucose results, largely from Chinese patients, ologliflozin achieved greater reductions in fasting blood glucose and 2-hour postprandial glucose.

At the same time, ologliflozin showed a favorable safety profile, with relatively mild gastrointestinal side effects, a lower rate of urinary tract infection than placebo, and no adverse reactions related to volume depletion.

HEC Pharm focuses on infection, chronic disease, and oncology. Since its establishment in 2003, it has built a rich pipeline of medicines. As its first approved innovative therapy in diabetes, ologliflozin may leverage the group’s channel advantages and academic capabilities established through five insulin products to compete in the highly heated glucose-lowering market. Behind it in the pipeline is HEC88473, a GLP-1/FGF21 dual agonist independently developed by HEC and the world’s first in its class to enter the clinic; overseas rights have already been partnered in a deal worth more than US$900 million.

Competition among SGLT2 inhibitors with the same mechanism has already become extremely intense. In China, six innovative drugs of this class had already been approved and all had entered the reimbursement list. Among them, dapagliflozin faces 33 marketed generics and 38 additional generic filings, counting only single-ingredient tablets, while empagliflozin has 42 marketed generics and 14 filings. In addition, multiple fixed-dose combinations based on the same mechanism have been developed, combining an SGLT2 inhibitor with a DPP4 inhibitor and/or metformin; Hengrui, for example, has already launched two such combinations, HR20031 and HR20033.

0
0
Loading